Home Contact Center Add this

Debiopharm International S.A.

developing & financing innovative drugs

Debiopharm International SA searches, evaluates and in-licenses promising drug candidates for development. Towards the end of the development process, the products are licensed out to pharmaceutical companies for world-wide marketing and sales.

 

 

Bertrand Ducrey

Bertrand Ducrey

Chief Executive Officer, Debiopharm International S.A.

Dr Ducrey received his Diploma of Pharmacy from the School of Pharmacy of Lausanne University, Switzerland in 1990 and then obtained his Ph.D. in Pharmaceutical Sciences in 1995. He joined Debiopharm Research & Manufacturing SA in 1995 as Pharmaceutical Project Manager. He then spent two years at Debiopharm International SA as Innovative Formulation Manager. In 2004, he returned to Debiopharm Research & Manufacturing to head the company as Chief Executive Officer until 2011. Since 2012, Dr Ducrey heads Debiopharm International SA as CEO.

Nigel McCracken

Nigel McCracken

Vice President, Translational Medicine, Debiopharm International S.A.

Dr McCracken obtained his BSc in Biochemistry/Pharmacology from Strathclyde University, UK in 1988 and a PhD in Biochemical Toxicology from Newcastle University, UK in 1991. Following a post-doctoral position in pharmacogenetics, Dr McCracken moved into pharma, where he worked for Charles River and Abbot Laboratories within the field of DMPK. In 2005, Dr McCracken moved to Altana Pharma/Nycomed (Konstanz, DE) as Senior Director of DMPK and then in 2008 became VP of Exploratory & Translational Development. In 2010 joined Shire (Eysins, VD) to Head up Translational Medicine, with a focus on implementing modern translational concepts of drug development with the ultimate goal to bring to the market and position medicines that matter. He joined Debiopharm International SA in 2014.

Stéphane Bernard

Stéphane Bernard

Director, Project Management Office, Debiopharm International S.A.

Dr Bernard received his Ph.D. in Organic Chemistry from the University of Lyon I, France, in 1999. The next year, he completed a Post-Doctorate at The School of Pharmacy Geneva-Lausanne, Switzerland. Dr Bernard has acquired several years of experience managing an R&D group, first involved in formulation and analytics then leading and coordinating cross-functional, multidisciplinary teams of the Translational Laboratory. He joined Debiopharm International SA in 2000.

Chris Freitag

Chris Freitag

Vice President, Clinical Research & Development, Debiopharm International S.A.

Dr Freitag obtained his Medical Degree from Kiel University, Germany in 1994. Following several posts in hematology/oncology, internal and respiratory medicine in the UK, Dr Freitag moved to Australia to work in emergency medicine and rural/remote practice for almost 4 years. In 2001, Dr Freitag moved to the pharmaceutical industry in Pharmacovigilance/drug Safety with Roche. After 6 years in PV and Medical Affairs, he joined Shire in the UK as Director of Clinical Medicine. At Shire, he held several positions in clinical development and medical affairs, covering the internal medicine portfolio, finally as VP, Global Clinical development and Innovation. In 2014 he joined BTG plc in the UK as SVP to Head up Vascular Medicine and went on to lead global clinical development across the portfolio in oncology, respiratory medicine, interventional vascular medicine and specialty pharmaceuticals/antidote products. He joined Debiopharm International SA in 2016.

Vanessa Currat

Vanessa Currat

General Counsel, Director IP and Legal Affairs, Debiopharm International S.A.

Vanessa Currat holds a Master of Business Law ("DESS") from the University of Paris V - René Descartes and a Master of International Economical Law from Paris I – La Sorbonne ("DEA"). She has more than 20 years of management experience in the biopharma industry with particular expertise in: negotiation of licensing and acquisition deals, Intellectual Property management including strategy conception and implementation, risk management, competition, corporate and labor law. She also has a successful track record in handling worldwide commercial and patent litigations. Prior responsibilities include positions at Kimbrough & Associates, Alcatel-Lucent, Vetrotech, and Debiotech. She joined Debiopharm International SA in 1996 where she served as lawyer and IP Counsel, becoming IP Manager in 2000. Since implementing the merge of the IP and Legal Services departments in 2006, she has been the head of Legal Affairs of Debiopharm Group. She joined the Executive Committee in 2014.

Houssam Ibrahim

Houssam Ibrahim

Vice President Pharmaceutical Development, Debiopharm International S.A.

Dr Ibrahim received his Diploma of Pharmacy from the Faculty of Sciences of the University of Geneva, Switzerland in 1983, and in 1989, obtained his Ph.D. in Sciences from the ‘Laboratoire de Pharmacie Galénique’, University of Geneva. Dr Ibrahim has acquired international experience in the pharmaceutical industry, including quality assurance, regulatory affairs, pharmaceutical sciences and GMP productions for clinical trial materials and commercial products. Previous job experiences include work in Quality Assurance and Regulatory Affairs at Serono. He joined Debiopharm International SA in 1992.

Peggy Lipp

Peggy Lipp

Director, Regulatory Affairs, Business Intelligence & Market Access, Debiopharm International S.A.

Mrs Lipp received her M.Sc. (Dipl. Ing.) degree in Biotechonology from Technical university of Graz in Austria and is experienced in leading the development of global regulatory strategies in a broad number of therapeutic areas for both early and late stage products. Before joining Debiopharm, Ms. Lipp was Director of Regulatory Affairs in Janssen, where she was directly responsible for successful key product approvals across multiple therapeutic areas. Prior to joining Janssen, she held multiple regulatory and research positions with increasing responsibilities in Biogen, Baxter, ApoPharma, and Mount Sinai School of Medicine. She joined Debiopharm in 2015 to lead Regulatory Affairs, Market Access and Business Intelligence teams.

Manuela Perraudin

Manuela Perraudin

Director, Human Resources, Debiopharm International S.A.

Mrs Perraudin obtained a Degree in International Relations from the Graduate Institute of International Studies in 1992 and a Master of Business Administration from the IMD, in 2002. With 21 years’ experience in Human Resources, she has held several senior management positions in the medical technology, hi-tech and engineering industries. She spent seven years at Medtronic Europe as Human Resources Director of the European Cardiovascular Division, subsequently held the position of Corporate Vice President Human Resources at Advanced Digital Broadcast and then became the Global Division Vice President Human Resources at IMI Hydronics, an organization including 6 manufacturing sites and 2000 employees in Europe, Asia and America. She joined Debiopharm International in 2014.

Alexandre Maret

Alexandre Maret

Director Finance and Administration - Debiopharm International S.A.

Mr Maret received his Enterprise Economist diploma from the University of Applied Sciences, Western Switzerland (HES SO)  in 1996. He has acquired an extensive experience in the accounting services of several companies (bank, international fiduciary, e-business). He joined Debiopharm International SA in 2005.

Debiopharm International S.A.

Forum "après-demain"
Chemin Messidor 5-7
Case postale 5911
1002 Lausanne
Switzerland

Tel. +41 (0)21 321 0111
Fax. +41 (0)21 321 0169